Sign in

    Ren Benjamin

    Managing Director and Senior Biotechnology Analyst at Citizen at JPM

    Ren Benjamin is a Managing Director and Senior Biotechnology Analyst at JMP Securities, focusing on small- and mid-cap companies in the healthcare and biotechnology sectors. He covers firms such as Inhibrx Biosciences, Werewolf Therapeutics, Summit Therapeutics, Prelude Therapeutics, BioAtla, Bicycle Therapeutics, and Kura Oncology, demonstrating a notable performance record with a success rate of approximately 60% and an average return of 6.93% across ratings. Beginning his career in the late 1990s, Benjamin has held analyst roles at previous firms before joining JMP Securities, where he has established himself as a leading voice in biotech equity research. He is FINRA-registered and holds active securities licenses, underscoring his credibility and expertise in the field.

    Ren Benjamin's questions to Blueprint Medicines (BPMC) leadership

    Ren Benjamin's questions to Blueprint Medicines (BPMC) leadership • Q3 2024

    Question

    Asked for details on the new direct-to-patient initiatives, their impact on SG&A, how their success is measured, and alternative strategies for market growth.

    Answer

    The company is investing in direct-to-patient campaigns to activate patients now that a prescriber base is established. The goal is to educate patients on what's possible beyond just coping with the disease, and hearing from other patients is a key part of this strategy to continue driving the launch.

    Ask Fintool Equity Research AI

    Ren Benjamin's questions to SELLAS Life Sciences Group (SLS) leadership

    Ren Benjamin's questions to SELLAS Life Sciences Group (SLS) leadership • Q2 2016

    Question

    Representing Ren Benjamin from Raymond James, an analyst asked what specific data from the NeuVax combination studies would be considered positive enough to warrant further development. He also questioned the development timelines for GALE-301 and GALE-302, considering the company's cash constraints and focus on anagrelide.

    Answer

    President and CEO Mark Schwartz responded that a clinically significant impact on disease-free survival (DFS) or recurrence rates would be very exciting. Regarding GALE-301 and GALE-302, he stated that the company aims to find a path forward for these earlier-stage programs that does not disrupt the higher-priority GALE-401, with development dependent on the company's future financial situation.

    Ask Fintool Equity Research AI